Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPO | P22079 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | HSD17B13 | Q7Z5P4 | 2/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9802974 | 0.79 | HSD17B13 (0.41) | KDM4EALDH1A1GSK3BMEN1MAPT | |
| SCHEMBL26034717 | 0.75 | LPO (0.40) | LPOALDH1A1HTTPOLB | |
| SCHEMBL4717518 | 0.74 | TDP1 (0.42) | KDM4EALDH1A1GSK3BHTTMEN1 | |
| SCHEMBL8527238 | 0.74 | LPO (0.36) | LPOALDH1A1HTTMEN1MAPT | |
| SCHEMBL8584050 | 0.70 | KMT2A (0.40) | LPOALDH1A1MEN1KMT2APOLB | |
| SCHEMBL9248493 | 0.70 | LPO (0.52) | LPOKDM4EGSK3BMEN1MAPT | |
| SCHEMBL8526952 | 0.70 | HSD17B10 (0.38) | KDM4EALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL14094219 | 0.69 | ALDH1A1 (0.43) | KDM4EALDH1A1POLBMAPK1 | |
| SCHEMBL26034442 | 0.69 | TSHR (0.43) | LPOALDH1A1 | |
| SCHEMBL8526760 | 0.69 | PKM (0.36) | LPOMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
| EP-2879710-A1 | AGENTS THAT MODULATE IMMUNE CELL ACTIVATION AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2015-06-10 | — | — | EP | disclosed |
| WO-2014022759-A1 | AGENTS THAT MODULATE IMMUNE CELL ACTIVATION AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-02-06 | — | — | WO | disclosed |
| EP-2531210-A1 | VACCINE AND METHODS OF USE AGAINST STRONGYLOIDES STERCORALIS INFECTION | The United States Of America As Represented By The Office of Technology Transfer, National Institutes Of Health (US) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011097216-A1 | VACCINE AND METHODS OF USE AGAINST STRONGYLOIDES STERCORALIS INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-08-11 | — | — | WO | disclosed |
| US-4171429-A | Pyrimidine to pyrimidine transformation process | RESEARCH CORPORATION (US) | 1979-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | PDE6C, PDE6A, PDE6D | LPO 252/4885KDM4E 3587/4885ALDH1A1 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.